Pharma major Dr. Reddy's Laboratories Ltd on Thursday announced the launch of Propofol Injectable Emulsion, USP, in the US market.

It's a therapeutic equivalent generic version of Diprivan (propofol) Injectable Emulsion, USP, approved by the US Food and Drug Administration (USFDA), the company said in a statement.

Dr. Reddy's Propofol Injectable Emulsion, USP, is available in 10 mg/mL vials for single patient use only.

The Hyderabad-based firm also made it clear that it will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection. It said it required the same commitment from wholesalers and distributors.

Dr. Reddy's said it was committed to providing affordable and innovative medicines for healthier lives. It neither condones nor supports the off-label use or misuse of its drugs.

"In the strongest possible terms, Dr. Reddy's objects to the use of any of its products to facilitate or otherwise aid lethal injections. Consistent with this position, Dr. Reddy's uses distribution controls to market Propofol Injectable Emulsion, USP."

The Diprivan brand and generic had US sales of approximately $310 million MAT for the most recent twelve months ending in November 2018, according to IMS Health.

--IANS

ms/mag/mr

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)